 To evaluate benefits of rAd-p53 gene therapy combined with radio- and chemo-therapy in treatment of unresectable, locally advanced head and neck cancer, total of 60 patients with above condition will be randomly assigned to two groups: the experiment group EG and the control group CG. The EG received multi-point injections of rAd-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 1012 viral particles VP in a 21-days cycle. Both EG and CG were given radiotherapy at a total dose of 60 Gy and chemotherapy Cisplatin 100 mgm2 IV on days 1 plus paclitaxel 30 mgm2 IV on day 1, 8 and 15. The patients will be treated until disease progression, withdrawal from study, or untolerated adverse events. study endpoints are efficacy Progression-free survival, overall survival and safety variables. 